Literature DB >> 12483414

Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease.

Henry Engler1, Per Olov Lundberg, Karl Ekbom, Inger Nennesmo, Anna Nilsson, Mats Bergström, Hideo Tsukada, Per Hartvig, Bengt Långström.   

Abstract

During the period February 1997 to April 2000, 15 patients with clinical symptoms of Creutzfeldt-Jakob disease (CJD) were referred to Uppsala University PET Centre. Positron emission tomography (PET) was performed to detect characteristic signs of the disease, e.g. neuronal death and/or astrocytosis in the brain. The examinations were performed in one session starting with oxygen-15 labelled water scan to measure regional cerebral blood flow, followed by imaging with the monoamine oxidase B inhibitor N-[(11)C-methyl]- L-deuterodeprenyl (DED) to assess astrocytosis in the brain and finally imaging with fluor-18 2-fluorodeoxyglucose (FDG) to assess regional cerebral glucose metabolism (rCMR(glu)) [corrected]. Nine of the patients fulfilled the clinical criteria of probable CJD. In eight of them, FDG and DED imaging revealed, in comparison with normal controls, a typical pattern characterized by a pronounced regional decrease (<2SD) in glucose brain metabolism, indicative of neuronal dysfunction; this was accompanied by a similar increase (>2SD) in DED binding, indicating astrocytosis. These changes were most pronounced in the cerebellum and the frontal, occipital and parietal cortices, whereas the pons, the thalamus and the putamen were less affected and the temporal cortex appeared unaffected. The cerebral blood flow showed a pattern similar to that observed with FDG. In the ninth patient, analysis with DED was not possible. The diagnosis of definite CJD according to international consensus criteria was confirmed in six of these patients. In one patient with probable CJD, protease-resistant prion protein (PrPres) could not be demonstrated. In two patients with probable CJD, autopsy was not allowed. Computed tomography and magnetic resonance imaging, performed in four and seven of these nine patients respectively, showed unspecific, mainly atrophic changes. In six other patients, the PET examinations gave a different pattern. In three of them, high rCMR(glu) was noticed in parts of the brain, particularly in the temporal lobes and basal ganglia, which could suggest encephalitis. One of the patients had Sjögren's syndrome, one had paraneoplastic limbic encephalitis and the third recovered spontaneously. In the other three patients, the DED binding was normal despite a hypometabolic glucose pattern. In conclusion, the PET findings obtained using DED and FDG paralleled neuropathological findings indicating neuronal dysfunction and astrocytosis, changes that are found in CJD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12483414     DOI: 10.1007/s00259-002-1008-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  26 in total

1.  Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?

Authors:  Agneta Nordberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-15       Impact factor: 9.236

2.  Imaging of neuroinflammation.

Authors:  Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12       Impact factor: 9.236

3.  Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.

Authors:  E Stefanova; A Wall; O Almkvist; A Nilsson; A Forsberg; B Långström; A Nordberg
Journal:  J Neural Transm (Vienna)       Date:  2005-07-29       Impact factor: 3.575

4.  Glucose metabolism in sporadic Creutzfeldt-Jakob disease: a statistical parametric mapping analysis of (18) F-FDG PET.

Authors:  E-J Kim; S-S Cho; B-H Jeong; Y-S Kim; S W Seo; D L Na; M D Geschwind; Y Jeong
Journal:  Eur J Neurol       Date:  2011-11-04       Impact factor: 6.089

5.  In vivo imaging of astrocytosis in Alzheimer's disease: an ¹¹C-L-deuteriodeprenyl and PIB PET study.

Authors:  Alexander Frizell Santillo; Juan Pablo Gambini; Lars Lannfelt; Bengt Långström; Luohija Ulla-Marja; Lena Kilander; Henry Engler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-19       Impact factor: 9.236

6.  Neuroimaging in human prion disease: Searching in the mist.

Authors:  Panayotis Ioannides; Dimitris Karacostas
Journal:  World J Radiol       Date:  2009-12-31

7.  Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Correlation of Histopathology and MRI in Prion Disease.

Authors:  Karin P Mente; James K O'Donnell; Stephen E Jones; Mark L Cohen; Nicolas R Thompson; Alberto Bizzi; Pierluigi Gambetti; Jiri G Safar; Brian S Appleby
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Jan-Mar       Impact factor: 2.703

8.  MRI detection of the cerebellar syndrome in Creutzfeldt-Jakob disease.

Authors:  Oren S Cohen; Chen Hoffmann; Hedok Lee; Joab Chapman; Robert K Fulbright; Isak Prohovnik
Journal:  Cerebellum       Date:  2009-05-01       Impact factor: 3.847

9.  Glucose metabolism in nine patients with probable sporadic Creutzfeldt-Jakob disease: FDG-PET study using SPM and individual patient analysis.

Authors:  Dimitri Renard; Rik Vandenberghe; Laurent Collombier; Pierre-Olivier Kotzki; Jean-Pierre Pouget; Vincent Boudousq
Journal:  J Neurol       Date:  2013-09-26       Impact factor: 4.849

10.  Imaging astrocytosis with PET in Creutzfeldt-Jakob disease: case report with histopathological findings.

Authors:  Henry Engler; Inger Nennesmo; Eva Kumlien; Juan Pablo Gambini; Po Lundberg; Irina Savitcheva; Bengt Långström
Journal:  Int J Clin Exp Med       Date:  2012-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.